Missed Nvidia? Buy Elon Musk’s “Silent Partner”

In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.

So please click here to see the details because a lot of people could get rich.

Gregory Korbel Biography and Net Worth

SVP of Aprea Therapeutics

Gregory A. Korbel., Ph.D. has served as our Chief Business Officer since March 2021, having previously served as Vice President, Business Development since July 2016. Dr. Korbel has more than 12 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson, and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University.

How do I contact Gregory Alan Korbel?: The corporate mailing address for Dr. Korbel and other Aprea Therapeutics executives is 535 BOYLSTON STREET, BOSTON MA, 02116. Aprea Therapeutics can also be reached via phone at 617-463-9385 and via email at [email protected]. Learn More on Gregory Alan Korbel's contact information.
Has Gregory Alan Korbel been buying or selling shares of Aprea Therapeutics?: Gregory Alan Korbel has not been actively trading shares of Aprea Therapeutics in the last ninety days. Most recently, Gregory Alan Korbel sold 1,375 shares of the business's stock in a transaction on Wednesday, December 1st. The shares were sold at an average price of $79.20, for a transaction totalling $108,900.00. Learn More on Gregory Alan Korbel's trading history.
Who are Aprea Therapeutics' active insiders?: Aprea Therapeutics' insider roster includes Lars Abrahmsen (SVP), Eyal Attar (SVP), and Gregory Korbel (SVP). Learn More on Aprea Therapeutics' active insiders.
Are insiders buying or selling shares of Aprea Therapeutics?: In the last year, Aprea Therapeutics insiders bought shares 10 times. They purchased a total of 52,160 shares worth more than $237,048.00. In the last year, insiders at the sold shares 1 times. They sold a total of 6,462 shares worth more than $29,595.96. The most recent insider tranaction occured on October, 23rd when CEO Oren Gilad bought 500 shares worth more than $1,960.00. Insiders at Aprea Therapeutics own 12.8% of the company. Learn More about insider trades at Aprea Therapeutics.
Information on this page was last updated on 10/23/2024.

Gregory Alan Korbel Insider Trading History at Aprea Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/1/2021	Sell	1,375	$79.20	$108,900.00
9/20/2021	Sell	1,648	$99.40	$163,811.20

Gregory Alan Korbel Buying and Selling Activity at Aprea Therapeutics

Aprea Therapeutics Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Today's Range

Now: $3.05

$3.02

$3.24

50 Day Range

MA: $3.47

$2.56

$4.45

2 Week Range

Now: $3.05

$2.15

$8.85

Volume

8,716 shs

Average Volume

20,358 shs

Market Capitalization

$16.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88